Skip to main content
BC Innovations
Feature Story

Export blockade for MS

Karyopharm is taking its nuclear export inhibitors to the clinic for MS

A new study from Karyopharm Therapeutics Inc. suggests the company's exportin 1 (XPO1; CRM1) inhibitors could have therapeutic applications beyond cancer. The researchers found that blocking the nuclear export protein has neuroprotective and anti-inflammatory activity that could help treat multiple sclerosis (MS).

XPO1 transports proteins from the nucleus to the cytoplasm. In most cancers, high levels of XPO1 promote tumor cell survival by transporting tumor suppressor proteins and growth factors. Removing tumor suppressors from the nucleus prevents their anti-cancer activity, while transporting growth factors into the cytoplasm makes them available to promote cancer growth.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial